Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 21,033 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune System Disorders Clear all

Conditions: Follicular Lymphoma
Interventions: PF-05280586, MabThera®; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 91
States / cities: Anaheim, California • Corona, California • Downey, California + 62 more

Conditions: Type 1 Diabetes, Children, Only
Interventions: telehealth visits; Other
Lead sponsor: Georgetown University; Other
Eligibility: 11 Years to 18 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Recombinant human hyaluronidase + immune globulin intravenous; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 16 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Centennial, Colorado • North Palm Beach, Florida • Dallas, Texas

Conditions: Asthma, Pregnancy
Interventions: Not listed
Lead sponsor: Jennifer McCallister MD; Other
Eligibility: 18 Years to 88 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Anakinra, Kineret, Atopic Dermatitis, Eczema, Allergic Disease
Interventions: Anakinra; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 10 Years to 30 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematologic Malignancies
Interventions: L-leucyl-L-leucine Methyl Ester (LLME), Fludarabine, Cytarabine, Cyclophosphamide, Tacrolimus, Mesna, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF), Hematopoietic stem cell transplantation (HSCT); Drug · Biological · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma
Interventions: In-Check Dial, Inhaler Device; Device
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 4 Years to 8 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Cancer, Lymphoma
Interventions: XL147 (SAR245408); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Augusta, Georgia • Boston, Massachusetts • Dallas, Texas

Conditions: Multiple Myeloma
Interventions: Panobinostat, Bortezomib, Dexamethasone, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 38
States / cities: Phoenix, Arizona • Anaheim, California • Concord, California + 34 more

Conditions: Lupus Nephritis
Interventions: CNTO 136, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more

Conditions: Lymphoma
Interventions: CMP-001, Pembrolizumab; Drug
Lead sponsor: Umar Farooq; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Spondyloarthropathy, Vasculitis
Interventions: VR-Biofeedback; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 6 more

Conditions: Hepatitis C, Human Immunodeficiency Virus
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: anti-thymocyte globulin, melphalan; Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Asthma
Interventions: BI 671800, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Huntington Beach, California • Mission Viejo, California • Stockton, California + 11 more

Conditions: Chronic Immune Thrombocytopenia, Primary Immune Thrombocytopenia, Adult Immune Thrombocytopenia
Interventions: No intervention; Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Seattle, Washington

Conditions: B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL, Follicular Lymphoma Grade 3B
Interventions: Fludarabine, Cyclophosphamide, CD22 CAR; Drug
Lead sponsor: Matthew Frank; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Urticaria
Interventions: AK002; Drug
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Edgewater, Florida • Cincinnati, Ohio

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Interventions: Clofarabine; Drug
Lead sponsor: New York Medical College; Other
Eligibility: Up to 30 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Vallhala, New York

Conditions: Graves' Disease
Interventions: IMVT-1402, Placebo; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 33
States / cities: Tucson, Arizona • Concord, California • Aurora, Colorado + 28 more

Conditions: Rheumatoid Arthritis
Interventions: Tirabrutinib, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 9
States / cities: Sacramento, California • Miami, Florida • Orlando, Florida + 6 more

Conditions: Multiple Myeloma
Interventions: Melphalan HCl for injection (propylene glycol free); Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
Interventions: HDM SLIT-tablet, Placebo; Biological · Other
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Miami, Florida • Columbus, Georgia • Ypsilanti, Michigan + 4 more

Search by objective public record fields.

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

Pediatric Boot Camp Program

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

A Comparison of Management Strategies of Asthma in Pregnancy

A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Evaluation of Negative Inspiratory Flow in Children With Acute Asthma

Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis

CMP-001 for Relapsed and Refractory Lymphoma

Feasibility of an Immersive Virtual Reality Based Biofeedback Intervention for Outpatients in Rheumatology

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma

Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria

Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

Mite Asthma Pediatric Immunotherapy Trial